The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients

Area of Science:

• Pulmonary and Cardiovascular Medicine
• Infectious Diseases
• Hematology

Background:

• Severe COVID-19 is associated with prothrombotic microvascular pathology and increased risk of venous thromboembolism.
• Early observational studies suggested low-molecular weight heparin (LMWH) adjunct therapy may lower mortality in COVID-19 patients.
• Optimal timing and dosage of LMWH in COVID-19 remain subjects of clinical debate.

Purpose of the Study:

• To elucidate the rationale for using LMWH in symptomatic COVID-19 patients.
• To review experimental and clinical evidence regarding LMWH in inflammatory conditions.
• To specifically consider findings from randomized controlled trials.

Main Methods:

• Systematic review of experimental studies on LMWH in inflammatory settings.
• Analysis of clinical data, including observational studies and randomized trials, on LMWH use in COVID-19.
• Focus on evidence related to timing and dosage of LMWH therapy.

Main Results:

• Evidence suggests LMWH may mitigate the prothrombotic state in COVID-19.
• Inflammatory processes in COVID-19 share similarities with other conditions where LMWH is beneficial.
• Randomized trials provide crucial data on efficacy and safety, though heterogeneity exists.

Conclusions:

• LMWH demonstrates potential as a therapeutic agent in managing COVID-19-associated coagulopathy.
• Further research and guideline refinement are necessary to establish definitive protocols for LMWH administration in COVID-19.
• Evidence from randomized trials is key to optimizing LMWH therapy for improved patient outcomes.